DocGo Inc. Files 8-K with Material Agreement Details

TL;DR

DocGo Inc. (DOCG) filed an 8-K on 10/20/25 detailing a material definitive agreement.

AI Summary

On October 20, 2025, DocGo Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements. DocGo Inc. was formerly known as Motion Acquisition Corp. until a name change on August 24, 2020.

Why It Matters

This 8-K filing provides crucial updates on significant agreements and financial information for DocGo Inc., impacting investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting a material definitive agreement and does not inherently indicate new risks.

Key Players & Entities

• DocGo Inc. (company) — Registrant
• Motion Acquisition Corp. (company) — Former company name
• October 20, 2025 (date) — Date of report
• August 24, 2020 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share DCGO The Nasdaq Stock Mar
• $25 m — or an aggregate purchase price of up to $25 million, consisting of $12.5 million in c
• $12.5 million — ice of up to $25 million, consisting of $12.5 million in cash payable at the closing of the T

Filing Documents

• ea0261755-8k_docgo.htm (8-K) — 41KB
• ea026175501ex99-1_docgo.htm (EX-99.1) — 21KB
• 0001213900-25-100412.txt ( ) — 237KB
• dcgo-20251020.xsd (EX-101.SCH) — 3KB
• dcgo-20251020_lab.xml (EX-101.LAB) — 33KB
• dcgo-20251020_pre.xml (EX-101.PRE) — 22KB
• ea0261755-8k_docgo_htm.xml (XML) — 4KB

01 Entry Into a Material Definitive

Item 1.01 Entry Into a Material Definitive Agreement. On October 20, 2025, Ambulnz Holdings, LLC (the "Purchaser"), a Delaware limited liability company and wholly-owned subsidiary of DocGo Inc. (the "Company"), a Delaware corporation, entered into an Agreement and Plan of Merger (the "Merger Agreement") with STMD Merger Company, LLC, a Delaware limited liability company ("MergerCo"), SteadyMD, Inc., a Delaware corporation (the "Acquired Company"), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative for the Indemnification Support Parties (as defined in the Merger Agreement), pursuant to which the Purchaser on October 20, 2025 has acquired the Acquired Company (the "Transaction") for an aggregate purchase price of up to $25 million, consisting of $12.5 million in cash payable at the closing of the Transaction (the "Closing Purchase Price") and up to $12.5 million as a contingent earn-out payment, payable (in cash or equity, at the Company's election) if certain performance conditions are met. The Closing Purchase Price is subject to a customary post-closing purchase price adjustment for working capital, indebtedness, transaction expenses and certain other items. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement. Pursuant to the Merger Agreement, upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware on October 20, 2025, the Acquired Company merged with and into MergerCo with MergerCo surviving. In connection with the Transaction, all Shares, Options, and Warrants were automatically cancelled (in each case, as defined in the Merger Agreement). The Merger Agreement contains customary representations and warranties and covenants of the Acquired Company and the Purchaser and the obligation of the Indemnification Support Parties to indemnify the Purchaser for a specified period of time for

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 20, 2025, the Company will issue a press release announcing entry into the Merger Agreement and completion of the acquisition of the Acquired Company pursuant to the Merger Agreement. The Company also announces that it will host a conference call and webcast tomorrow at 11:00 a.m. ET to discuss the Transaction. Conference call and webcast details are included below and will be included in the press release. A copy of the presentation to be used in connection with the conference call and webcast will be made available on the Company's website shortly ahead of the call. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Conference Call and Webcast Details Tuesday October 21st, 2025 at 11:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1739677&tp_key=1f035a2246 The information in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 20, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL). *** 1

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including condition, projections and results of operations, and the accuracy of any assumptions underlying any of the foregoing. These statements are based on the beliefs and assumptions of the Company's management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such the Company's future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "might," "will," "should," "could," "can," "would," "design," "potential," "seeks," "plans," "scheduled," "anticipates," "intends" or the negative of these terms or similar expressions.

Forward-looking statements are inherently subject to substantial risks,

Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company's control, and which may cause its actual results or outcomes, or the timing of its results or outcomes, to differ materially from those contained in its forward-looking statements, including, but not limited to the following: the risk that the cost savings and synergies from the Transaction may not be fully realized or may take longer than anticipated to be realize; disruption to the parties' businesses as a result of the Transaction and associated integration activities; reputational risk and potential adverse reactions of SteadyMD or DocGo customers, employees, vendors, contractors or other business partners, including those resulting from the announcement or completion of the Transaction; the extent to which SteadyMD's business will perform consistent with management's expectations and projections; accuracy of projections; impacts related to accelerated wind down of migrant-related services; uncertainties related to future non-migrant municipal population health revenue; the Company's ability to return to profitability and/or expand its programs with insurance partners, hospital systems, municipalities and other strategic partners; the Company's ability to successfully implement its business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying its line of credit; the Company's ability to establish, maintain and grow customer relationships; the Company's ability to execute projects to the satisfaction of its customers; the Company's ability to grow demand for its care gap closure programs; the Company's ability to maintain or grow its cash balances; the Company's reliance on and ability to maintain its contractual relationships with its healthcare provider partners and other strategic partners; the Company's ability to compete effectively in a highly c

View Full Filing

View this 8-K filing on SEC EDGAR